A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: ITU512
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals